News

US Health Secretary Kennedy Looks to Fast-Tracking Approvals for Rare Disease Drugs
(Reuters) -Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would ...
TMCnet2d
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...
manilatimes1mon
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven ...
Mena FN1mon
Dyne Therapeutics Announces Chief Business Officer And Chief Scientific Officer Appointments
WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...
Yahoo Finance2mon
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...
The Globe and Mail3mon
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Feb. 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with ...
Nasdaq4mon
Dyne Therapeutics to Present New Clinical Data from Phase 1/2 ACHIEVE Trial on January 10, 2025
Dyne Therapeutics, a clinical-stage company focused on therapeutics for genetically driven neuromuscular diseases, announced that it will present new clinical data from its Phase 1/2 ACHIEVE trial ...